KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors

Cancer Research

Volumn 73, Issue 18, 2013, Pages 5775-5786

  Corbin, Amie S ^a,b   O'Hare, Thomas ^c,d   Gu, Zhimin ^c   Kraft, Ira L ^c   Eiring, Anna M ^c   Khorashad, Jamshid S ^c   Pomicter, Anthony D ^c,d   Zhang, Tian Y ^c,d   Eide, Christopher A ^a,b   Manley, Paul W ^e   Cortes, Jorge E ^f   Druker, Brian J ^a,b   Deininger, Michael W ^c,d  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d UNIVERSITY OF UTAH   (United States)

^e NOVARTIS PHARMA AG   (Switzerland)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; DASATINIB; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR;

ANIMAL CELL; ARTICLE; BONE MARROW; CANCER CELL CULTURE; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; LEUKEMIA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STEM CELL; STROMA CELL;

ANIMALS; ANTIGENS, CD34; APOPTOSIS; BENZAMIDES; BLOTTING, WESTERN; CELL DIFFERENTIATION; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; NEOPLASTIC STEM CELLS; PHOSPHATIDYLINOSITOL 3-KINASES; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STEM CELL FACTOR; STROMAL CELLS; TUMOR CELLS, CULTURED;

EID: 84884752554     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-1318     Document Type: Article

References (43)

1. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-17.
2. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005;105: 2640-53.
3. Dewar AL, Cambareri AC, Zannettino AC, Miller BL, Doherty KV, Hughes TP, et al. Macrophage colony-stimulating factor receptor cfms is a novel target of imatinib. Blood 2005;105:3127-32.
4. Manley PW, Stiefl N, Cowan-Jacob SW, Kaufman S, Mestan J, Wartmann M, et al. Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib. Bioorg Med Chem 2010;18:6977-86.
5. Al-Ali HK, Heinrich MC, Lange T, Krahl R, Mueller M, Muller C, et al. High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib. Hematol J 2004; 5:55-60.
6. Braconi C, Bracci R, Cellerino R. Molecular targets in Gastrointestinal Stromal Tumors (GIST) therapy. Curr Cancer Drug Targets 2008; 8:359-66.
7. Cross NC, Reiter A. Fibroblast growth factor receptor and plateletderived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders. Acta Haematol 2008;119:199-206.
8. Cortes J, O'Brien S, Quintas A, Giles F, Shan J, Rios MB, et al. Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase. Cancer 2004;100:2396-402.
9. Sneed TB, Kantarjian HM, Talpaz M, O'Brien S, Rios MB, Bekele BN, et al. The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase. Cancer 2004;100:116-21.
10. Deininger MW, Manley P. What do kinase inhibition profiles tell us about tyrosine kinase inhibitors used for the treatment of CML? Leuk Res 2012;36:253-61.
11. Pierce A, Spooncer E, Ainsworth S, Whetton AD. BCR-ABL alters the proliferation and differentiation response of multipotent hematopoietic cells to stem cell factor. Oncogene 2002;21:3068-75.
12. Hallek M, Danhauser-Riedl S, Herbst R, Warmuth M,Winkler A, Kolb HJ, et al. Interaction of the receptor tyrosine kinase p145c-kit with the p210bcr/abl kinase in myeloid cells. Br J Haematol 1996;94: 5-16.
13. Moore S, Haylock DN, Levesque JP, McDiarmid LA, Samels LM, To LB, et al. Stem cell factor as a single agent induces selective proliferation of the Philadelphia chromosome positive fraction of chronic myeloid leukemia CD34() cells. Blood 1998;92:2461-70.
14. Agarwal R, Doren S, Hicks B, Dunbar CE. Long-term culture of chronic myelogenous leukemia marrow cells on stem cell factor-deficient stroma favors benign progenitors. Blood 1995;85:1306-12.
15. Wong S, McLaughlin J, Cheng D, Zhang C, Shokat KM, Witte ON. Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations. Proc Natl Acad Sci U S A 2004;101: 17456-61.
16. Belloc F, Airiau K, Jeanneteau M, Garcia M, Guerin E, Lippert E, et al. The stem cell factor-c-KIT pathway must be inhibited to enable apoptosis induced by BCR-ABL inhibitors in chronic myelogenous leukemia cells. Leukemia 2009;23:679-85.
17. Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest 2011;121: 396-409.
18. Zhou T, Parillon L, Li F, Wang Y, Keats J, Lamore S, et al. Crystal structure of the T315I mutant of AbI kinase. Chem Biol Drug Des 2007; 70:171-81.
19. Melnick JS, Janes J, Kim S, Chang JY, Sipes DG, Gunderson D, et al. An efficient rapid system for profiling the cellular activities of molecular libraries. Proc Natl Acad Sci U S A 2006;103:3153-8.
20. Manley PW, Drueckes P, Fendrich G, Furet P, Liebetanz J, Martiny- Baron G, et al. Extended kinase profile and properties of the protein kinase inhibitor nilotinib. Biochim Biophys Acta 2010;1804:445-53.
21. Snead JL, O'Hare T, Adrian LT, Eide CA, Lange T, Druker BJ, et al. Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis. Blood 2009;114:3459-63.
22. O'Hare T, Eide CA, Deininger MW. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 2007;110:2242-9.
23. Bock TA. Assay systems for hematopoietic stem and progenitor cells. Stem Cells 1997;15(Suppl 1):185-95.
24. Petzer AL, Eaves CJ, Lansdorp PM, Ponchio L, Barnett MJ, Eaves AC. Characterization of primitive subpopulation of normal and leukemic cells present in the blood of patients with newly diagnosed as well as established chronic myeloid leukemia. Blood 1996;88:2162-71.
25. Ronnstrand L. Signal transduction via the stem cell factor receptor/c- Kit. Cell Mol Life Sci 2004;61:2535-48.
26. Strife A, Wisniewski D, Liu C, Lambek CL, Darzynkiewicz Z, Silver RT, et al. Direct evidence that Bcr-Abl tyrosine kinase activity disrupts normal synergistic interactions between Kit ligand and cytokines in primary primitive progenitor cells. Mol Cancer Res 2003;1:176-85.
27. O'Hare T, Eide CA, Agarwal A, Adrian LT, Zabriskie MS, Mackenzie RJ, et al. Threshold levels of ABL tyrosine kinase inhibitors retained in chronic myeloid leukemia cells define commitment to apoptosis. Cancer Res 2013;73:3356-70.
28. Lennartsson J, Wernstedt C, Engstrom U, Hellman U, Ronnstrand L. Identification of Tyr900 in the kinase domain of c-Kit as a Src-dependent phosphorylation site mediating interaction with c-Crk. Exp Cell Res 2003;288:110-8.
29. von Lindern M, Schmidt U, Beug H. Control of erythropoiesis by erythropoietin and stem cell factor: a novel role for Bruton's tyrosine kinase. Cell Cycle 2004;3:876-9.
30. Deininger M, Goldman JM, Lydon NB, Melo JV. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL positive cells. Blood 1997;90:3691-8.
31. Hamilton A, Helgason GV, Schemionek M, Zhang B, Myssina S, Allan EK, et al. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood 2012;119:1501-10.
32. Copland M, Hamilton A, Elrick LJ, Baird JW, Allan EK, Jordanides N, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006;107:4532-9.
33. Copland M, Pellicano F, Richmond L, Allan EK, Hamilton A, Lee FY, et al. BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergises with tyrosine kinase inhibitors. Blood 2008;111:2843-53.
34. Manz MG. Human-hemato-lymphoid-system mice: opportunities and challenges. Immunity 2007;26:537-41.
35. Chomel JC, Bonnet ML, Sorel N, Bertrand A, Meunier MC, Fichelson S, et al. Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease. Blood 2011;118:3657-60.
36. Chu S, McDonald T, Lin A, Chakraborty S, Huang Q, Snyder DS, et al. Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. Blood 2011;118:5565-72.
37. Naka K, Hoshii T, Muraguchi T, Tadokoro Y, Ooshio T, Kondo Y, et al. TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature 2010;463:676-80.
38. Mekori YA, Metcalfe DD. Transforming growth factor-beta prevents stem cell factor-mediated rescue of mast cells from apoptosis after IL- 3 deprivation. J Immunol 1994;153:2194-203.
39. Puttini M, Coluccia AM, Boschelli F, Cleris L, Marchesi E, Donella- Deana A, et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl neoplastic cells. Cancer Res 2006;66:11314-22.
40. Cortes JE, Kim DW, Kantarjian HM, Brummendorf TH, Dyagil I, Griskevicius L, et al. Bosutinib versus imatinib in newly diagnosed chronicphase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol 2012;30:3486-92.
41. Khoury HJ, Cortes JE, Kantarjian HM, Gambacorti-Passerini C, Baccarani M, Kim DW, et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood 2012;119:3403-12.
42. Linnekin D, DeBerry CS, Mou S. Lyn associates with the juxtamembrane region of c-Kit and is activated by stem cell factor in hematopoietic cell lines and normal progenitor cells. J Biol Chem 1997;272: 27450-5.
43. Kimura Y, Jones N, Kluppel M, Hirashima M, Tachibana K, Cohn JB, et al. Targeted mutations of the juxtamembrane tyrosines in the Kit receptor tyrosine kinase selectively affect multiple cell lineages. Proc Natl Acad Sci U S A 2004;101:6015-20.